全文获取类型
收费全文 | 7698篇 |
免费 | 426篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 218篇 |
妇产科学 | 108篇 |
基础医学 | 1045篇 |
口腔科学 | 155篇 |
临床医学 | 451篇 |
内科学 | 2172篇 |
皮肤病学 | 142篇 |
神经病学 | 537篇 |
特种医学 | 337篇 |
外科学 | 946篇 |
综合类 | 33篇 |
一般理论 | 1篇 |
预防医学 | 316篇 |
眼科学 | 120篇 |
药学 | 674篇 |
中国医学 | 40篇 |
肿瘤学 | 781篇 |
出版年
2023年 | 33篇 |
2022年 | 26篇 |
2021年 | 146篇 |
2020年 | 111篇 |
2019年 | 146篇 |
2018年 | 165篇 |
2017年 | 132篇 |
2016年 | 174篇 |
2015年 | 181篇 |
2014年 | 257篇 |
2013年 | 298篇 |
2012年 | 458篇 |
2011年 | 534篇 |
2010年 | 307篇 |
2009年 | 247篇 |
2008年 | 374篇 |
2007年 | 464篇 |
2006年 | 398篇 |
2005年 | 433篇 |
2004年 | 374篇 |
2003年 | 337篇 |
2002年 | 341篇 |
2001年 | 169篇 |
2000年 | 208篇 |
1999年 | 212篇 |
1998年 | 68篇 |
1997年 | 59篇 |
1996年 | 53篇 |
1995年 | 58篇 |
1994年 | 39篇 |
1993年 | 51篇 |
1992年 | 126篇 |
1991年 | 118篇 |
1990年 | 115篇 |
1989年 | 131篇 |
1988年 | 110篇 |
1987年 | 87篇 |
1986年 | 89篇 |
1985年 | 98篇 |
1984年 | 53篇 |
1983年 | 38篇 |
1982年 | 21篇 |
1979年 | 45篇 |
1975年 | 24篇 |
1973年 | 26篇 |
1972年 | 24篇 |
1970年 | 27篇 |
1969年 | 24篇 |
1968年 | 24篇 |
1967年 | 20篇 |
排序方式: 共有8183条查询结果,搜索用时 31 毫秒
1.
Tsuneo Saga Yuji Nakamoto Takayoshi Ishimori Takahiro Inoue Yoichi Shimizu Hiroyuki Kimura Shusuke Akamatsu Takayuki Goto Hiroyuki Watanabe Kosuke Kitaguchi Masao Watanabe Masahiro Ono Hideo Saji Osamu Ogawa Kaori Togashi 《Cancer science》2019,110(2):742-750
This first‐in‐man study was carried out to evaluate the safety, whole‐body distribution, dose estimation, and lesion accumulation of 18F‐FSU‐880, a newly developed probe targeting prostate‐specific membrane antigen. Six prostate cancer patients with known metastatic lesions underwent serial whole‐body PET/computed tomography (CT) with 18F‐FSU‐880. Blood and urine were analyzed before and after PET/CT. Accumulation of 18F‐FSU‐880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole‐body effective dose were calculated using OLINDA/EXM software was developed by Dr. Michael Stabin of Vanderbilt University, Nashville, Tennessee, USA. 18F‐FSU‐880 PET/CT could be carried out without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 × 10?2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in 1 patient, whose bone metastases were well‐controlled and inactive. The PET/CT with 18F‐FSU‐880 could be carried out safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of 18F‐FSU‐880 PET/CT in the management of prostate cancer patients. 相似文献
2.
3.
4.
5.
6.
7.
Takayuki Suzuki Hideaki Shimada Mitsunori Ushigome Junichi Koike Kimihiko Funahashi Tetsuo Nemoto Hironori Kaneko 《Clinical journal of gastroenterology》2016,9(2):55-58
The overexpression of mutant p53 stimulates serum p53 antibody production in patients with colorectal carcinoma even in superficial tumors. Although the short-term perioperative monitoring of serum p53 antibody titers is reported to be useful in predicting tumor recurrence and patient survival in colorectal carcinoma, the clinical utility of the long-term monitoring of serum p53 antibody titers in patients with colorectal cancer remains unknown. Here, we report the 3-year monitoring of serum p53 antibody titers in a 60-year-old man with rectal cancer, clinical stage IV (T2N2M1b, lung and liver metastases), who was treated with chemotherapy and surgery. Screening tests for CEA (29.4 ng/ml), CA19-9 (41.1 U/ml), and serum p53 antibody (2170 U/ml) were positive before treatment. After chemotherapy with mFOLFOX6 + bevacizumab (B-mab), CEA and CA19-9 decreased to the normal range. However, serum p53 antibody titer remained positive (283 U/ml). After low anterior resection, the serum p53 antibody titer still remained positive (63.4 U/ml). Serum p53 antibody titer significantly changed and was associated with treatment response and tumor recurrence. In the last 6 months of the patient’s life, serum p53 antibody titer gradually decreased, which possibly reflects the modification of the patient’s immune response to p53 antigens. 相似文献
8.
Obesity exacerbates imiquimod‐induced psoriasis‐like epidermal hyperplasia and interleukin‐17 and interleukin‐22 production in mice 下载免费PDF全文
Kaori Kanemaru Ayano Matsuyuki Yoshikazu Nakamura Kiyoko Fukami 《Experimental dermatology》2015,24(6):436-442
Psoriasis is a chronic inflammatory skin disorder that is accompanied by an imbalance between the proliferation and differentiation of keratinocytes. A number of studies have suggested an association between obesity and severe psoriasis; however, it remains to be clarified whether obesity exacerbates psoriasis. To address this unsolved question, we induced psoriasiform dermatitis in mouse models for obesity. We found that obesity exaggerated the severity of psoriasiform dermatitis induced by topical application of the Toll‐like receptor (TLR) 7 agonist, imiquimod. Ear swelling and epidermal hyperplasia were more prominent in the obese mice than in the control mice. When compared to imiquimod‐treated control mice, imiquimod‐treated obese mice expressed higher levels of psoriasis mediators, interleukin‐17A (IL‐17A) and IL‐22 in the skin. Food intake restriction partially abrogated enhanced ear swelling and cytokine overproduction in obese mice. Furthermore, the obesity environment and imiquimod treatment synergistically induced an IL‐17A downstream molecule, regenerating islet‐derived 3γ (Reg3γ), which is a critical molecule for psoriatic epidermal hyperplasia. Palmitic acid, one of the fatty acids released by subcutaneous adipocytes, increased the expression of REG3A (a human homologue of mouse Reg3γ) in both the HaCaT keratinocyte cell line and normal human keratinocytes. Taken together, these results strongly suggest that obesity exacerbates psoriasiform dermatitis in mice by upregulating IL‐17A, IL‐22 and Reg3γ. 相似文献
9.
10.
Koji Tokunaga Akihiro Furuta Hiroyoshi Isoda Shinji Uemoto Kaori Togashi 《Diagnostic and interventional radiology (Ankara, Turkey)》2021,27(1):65
PURPOSEWe aimed to evaluate mid- to long-term results of endovascular treatment for portal vein thrombosis (PVT) after living-donor liver transplantation (LDLT).METHODSThirty cases (14 males, 16 females; age range, 0.67–65 years) who underwent endovascular treatment including thrombolysis, angioplasty, stent placement, and/or collateral embolization for PVT after LDLT from 2001 to 2017 were retrospectively reviewed. Clinical and procedural data were collected and analyzed regarding the patency of the PVT site at the last follow-up date (PVT-free persistency) using Log-rank test. Results were considered statistically significant at p < 0.05.RESULTSMedian follow-up was 120 months. The technical success rate was 80% (n=24). Patency rates at 1 week and 1, 3, 6, 12, 36, and 60 months were 73%, 59%, 55%, 51%, 51%, 51%, and 51% for primary patency and 80%, 70%, 66%, 66%, 66%, 61%, and 61% for assisted patency after secondary endovascular treatment. PVT-free persistency rates regarding the subgroups were as follows: children under 12 years vs. adults, 50% vs. 68% (p = 0.42); acute vs. nonacute, 76% vs. 46% (p = 0.10); localized vs. extensive, 90% vs. 50% (p = 0.035); transileocolic approach vs. percutaneous-transhepatic approach, 71% vs. 54% (p = 0.39); and thrombolysis-based treatment vs. non-thrombolysis-based treatment, 71% vs. 44% (p = 0.12), respectively. Among technically successful cases, PVT-free persistency rate was 94% for those with hepatopetal flow in the peripheral portal vein vs. 17% for those without hepatopetal flow (p < 0.001). The only major complication occurring was pleural hemorrhage (n=1). Minor complications (i.e., fever) occurred in 18 patients (60%).CONCLUSIONIn conclusion, mid- to long-term portal patency following endovascular treatment was approximately 50%–60% in PVT patients after LDLT. PVT site patency over three months after the first endovascular treatment, localized PVT, and hepatopetal flow in the peripheral portal vein were identified as key prognostic factors for mid- to long-term portal patency.Portal vein thrombosis (PVT) is a vascular complication of living-donor liver transplantation (LDLT), with an estimated incidence of up to 4% (1, 2). The risk of vascular complications, including PVT, is higher in LDLT compared with conventional deceased-donor liver transplantation, because of the smaller vessels, insufficient vessel length for reconstruction, neointimal proliferation, and higher risk of twisting and kinking of the vascular pedicle (3) due to smaller graft size than in deceased-donor liver transplantation. PVT after LDLT can lead to graft failure and the need for retransplantation or death (2), making immediate treatment crucial.Endovascular-based treatment is one option for treating PVT. The utility of target-focused thrombolysis, balloon angioplasty, and stent placement to restore portal flow has been reported previously (4–10). However, the efficacy of endovascular treatment after LDLT has only been presented in some case reports (11, 12) and the mid- to long-term outcomes remain unclear.The purpose of this study was to evaluate the technical success, feasibility, and mid- to long-term results of endovascular treatment for PVT after LDLT in our institution. 相似文献